| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 4,242 | 4,338 | 12.03. | |
| 4,252 | 4,339 | 12.03. |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 4,900 | 4.500 | |||
| 4,880 | 4.000 | |||
| 4,770 | 285 | |||
| 4,750 | 2.700 | |||
| 4,680 | 1.000 | |||
| 4,550 | 54.500 | |||
| 4,445 | 3.800 | |||
| 4,344 | 4.098 | |||
| 4,339 | 1.482 | |||
| 4,300 | 1.000 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/evt.htm [/URL] | ||||
| 1.482 | 4,252 | |||
| 335 | 4,250 | |||
| 4.098 | 4,247 | |||
| 15.050 | 4,200 | |||
| 6.050 | 4,150 | |||
| 500 | 4,120 | |||
| 900 | 4,100 | |||
| 7.000 | 4,080 | |||
| 3.400 | 4,000 | |||
| 1.200 | 3,980 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 40.015 | 1,933 | 77.365 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 17:35:24 | 4,305 | 158.476 |
| 17:29:32 | 4,285 | 3 |
| 17:29:15 | 4,287 | 532 |
| 17:29:12 | 4,283 | 133 |
| 17:29:12 | 4,283 | 676 |
| 17:29:07 | 4,278 | 146 |
| 17:29:02 | 4,278 | 100 |
| 17:28:47 | 4,279 | 54 |
| 17:28:36 | 4,279 | 274 |
| 17:25:50 | 4,285 | 31 |
| 17:24:59 | 4,294 | 228 |
| 17:24:33 | 4,290 | 75 |
| 17:24:30 | 4,281 | 6 |
| 17:24:30 | 4,290 | 75 |
| 17:24:28 | 4,290 | 19 |
| 17:24:25 | 4,281 | 73 |
| 17:24:25 | 4,291 | 102 |
| 17:23:08 | 4,294 | 103 |
| 17:23:01 | 4,295 | 94 |
| 17:22:25 | 4,301 | 1.728 |
| Tagesumsatz Xetra | -0,047 -1,08 % | 1,3 Mio. |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Eilmeldung am Abend: EVOTEC SE wackelt - meine Chance? | 92 | Maximilian Berger | ||
| Do | Evotec: Eine klare Enttäuschung | 992 | 4investors | Die Analysten der Deutschen Bank bezeichnen das Strategie-Update von Evotec als enttäuschend. 2026 sollen die Umsätze noch stärker als 2025 zurückgehen. Das bereinigte EBITDA soll sich auf rund 20 Millionen... ► Artikel lesen | |
| Do | Evotec slashes staff as turnaround plan gathers pace | 46 | pharmaphorum | ||
| Do | EILMELDUNG: Könnte die Evotec-Aktie jetzt komplett durchstarten? | Hebelschein-Spekulant | |||
| EVOTEC Aktie jetzt für 0€ handeln | |||||
| Do | Breaking News! Takeover speculation? BioNTech, Evotec, Vidac Pharma | 202 | The Market Herald Canada |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| Do | Trinity Biotech plc: Trinity Biotech Begins Rollout of Innovative Glucose Monitoring System In Key Market Following Regulatory Approval of Next-Generation Premier Hb9210 HbA1c Column System | GlobeNewswire (Europe) | Company begins roll out of innovative diabetes care HbA1c column system in Brazil Commercial leadership strengthened with key appointment DUBLIN, March 12, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech... ► Artikel lesen | |
| Do | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update | GlobeNewswire (Europe) | $106.5 million cash position as of December 31, 2025 to be further enhanced by $35 million expected from Medtronic and Ligand in Q2 2026 from previously announced transactions, as well as Haemonetics'... ► Artikel lesen | |
| Do | FibroBiologics, Inc.: FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology | GlobeNewswire (Europe) | HOUSTON, March 12, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the... ► Artikel lesen | |
| Do | Cyberattack Disrupts Systems At Medical Device Maker Stryker | AFX News | WASHINGTON (dpa-AFX) - Stryker Corporation said it experienced a global network disruption after a cyberattack targeting its Microsoft environment, with pro-Iran hackers claiming responsibility... ► Artikel lesen | |
| Do | Molecular Partners Reports Highlights and Financial Results for Full Year 2025 | GlobeNewswire (Europe) | Initiated US Phase 1/2a study of DLL3-targeting 212Pb-based Radio-DARPin candidate MP0712 for SCLC and other neuroendocrine cancers, co-developed with strategic partner Orano Med; initial data anticipated... ► Artikel lesen |